Roche Holding AG (ROGN MX) stock market data APIs
₱6690.0444
0(0%)
as of November 4, 2025
Try our APIs with
free plan!
Roche Holding AG Financial Data Overview
Price chart is built with
Anychart
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Prev. Close
6690.0444
Open
6690.0444
High
6690.0444
Low
6690.0444
52 wk Range
5002-6938.8829
Market Cap
4 843 970 M
P/E Ratio
24.9377
Shares Outstanding
690 M
Revenue
63 488 M
Dividends (Yield)
0.0014
Beta
0.169
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 63 488 M
- EBITDA: 23 429 M
- Earnings Per Share: 268
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News
New
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis, Inc. EXEL reported better-than-expected results for the third quarter of 2025. Adjusted earnings of 78 cents per share beat the Zacks Consensus Estimate of 68 cents. The company registered ...
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
Corcept Therapeutics CORT reported third-quarter 2025 earnings of 16 cents per share, which missed the Zacks Consensus Estimate of 18 cents. The company had reported earnings of 41 cents per share in ...
CNS Summit releases annual Digital Innovation Index
BOSTON, Nov. 5, 2025 /PRNewswire/ -- The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting...
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
Recursion Pharmaceuticals Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
